Article Text

New Therapy
First antibody therapy in veterinary medicine launched for dogs in the UK

Statistics from

THE first monoclonal antibody approved for veterinary use in the European Union, Cytopoint, was launched this week.

A single injection of Cytopoint treats the clinical signs of atopic dermatitis in dogs, including itch and inflammation, for up to one month.

The monoclonal antibody (MAb) treatment works by mimicking the activity of natural antibodies to selectively bind to and neutralise interleukin 31 (IL-31), a key protein involved in cell communication which triggers itching associated with atopic dermatitis in dogs. Because it neutralises IL-31, it has been demonstrated not to interfere with the immune response, meaning that it does not induce unintended immunosuppression or enhancement.

Manufacturer Zoetis says treatment provides long-lasting relief from itching and inflammation within eight hours, allowing damaged skin to heal, in this way it improves the long-term quality of life for atopic dogs and their owners.

Embedded Image

Photograph: Zoetis

This dog had a long history of chronic atopic dermatitis. Treatments with corticosteroids, cyclosporine, oclacitinib, allergen-specific immunotherapy and a home-cooked hypoallergenic diet had failed. The picture below shows the dog seven weeks after the first injection with cytopoint

Photograph: Zoetis

In clinical studies submitted to the European Medicines Agency, the efficacy of cytopoint was evaluated and …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.